Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Prosperini

Showing results (171-180 of 182) with videos related to

Pageof 19
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|September 29, 2023
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS StudySerena Ruggieri, Luca Prosperini, Sarmad Al-Araji, et al.
Therapeutic Advances in Neurological Disorders|December 31, 2025
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian studyMatteo Lucchini, Giovanna Borriello, Shalom Haggiag, et al.
Neurology|November 23, 2021
Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying TherapiesCarla Tortorella, Alessandra Aiello, Claudio Gasperini, et al.
Journal of Neurology|November 14, 2019
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison studyLuca Prosperini, Antonio Cortese, Matteo Lucchini, et al.
Vaccines|July 27, 2024
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS StudyAlessandra Vergori, Giulia Matusali, Eleonora Cimini, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 19, 2021
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosisMassimiliano Di Filippo, Cinzia Cordioli, Simona Malucchi, et al.
Brain : a Journal of Neurology|September 13, 2015
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Carlo Pozzilli, et al.
Neurology|November 3, 2017
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter studyAlice Laroni, Alessio Signori, Giorgia T Maniscalco, et al.
European Journal of Neurology|December 11, 2020
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre studyMaria Di Gregorio, Valentina Liliana Adriana Torri Clerici, Giuseppe Fenu, et al.
Journal of Neurology|February 22, 2021
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy studySebastiano Bucello, Pietro Annovazzi, Paolo Ragonese, et al.
Pageof 19

Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Journal of Neurology, Neurosurgery, and Psychiatry|September 29, 2023
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS StudySerena Ruggieri, Luca Prosperini, Sarmad Al-Araji, et al.
Therapeutic Advances in Neurological Disorders|December 31, 2025
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian studyMatteo Lucchini, Giovanna Borriello, Shalom Haggiag, et al.
Neurology|November 23, 2021
Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying TherapiesCarla Tortorella, Alessandra Aiello, Claudio Gasperini, et al.
Journal of Neurology|November 14, 2019
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison studyLuca Prosperini, Antonio Cortese, Matteo Lucchini, et al.
Vaccines|July 27, 2024
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS StudyAlessandra Vergori, Giulia Matusali, Eleonora Cimini, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 19, 2021
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosisMassimiliano Di Filippo, Cinzia Cordioli, Simona Malucchi, et al.
Brain : a Journal of Neurology|September 13, 2015
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Carlo Pozzilli, et al.
Neurology|November 3, 2017
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter studyAlice Laroni, Alessio Signori, Giorgia T Maniscalco, et al.
European Journal of Neurology|December 11, 2020
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre studyMaria Di Gregorio, Valentina Liliana Adriana Torri Clerici, Giuseppe Fenu, et al.
Journal of Neurology|February 22, 2021
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy studySebastiano Bucello, Pietro Annovazzi, Paolo Ragonese, et al.
Pageof 19